Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 53: 1976-1977, 2007; 10.1373/clinchem.2007.094276
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfäfflin, A.
Right arrow Articles by Müssig, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfäfflin, A.
Right arrow Articles by Müssig, K.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2007;53:1976-1977.)
© 2007 American Association for Clinical Chemistry, Inc.


Letters to the Editor

3-O-Methyldopamine (3-O-Methoxytyramine) Interferes with the Internal Standard 3,4-Dihydroxybenzylamine in a Plasma Catecholamine HPLC Method

Albrecht Pfäfflin, Erwin Schleicher and Karsten Müssiga

Department of Internal Medicine IV, Clinical Chemistry University of Tuebingen Tuebingen, Germany

aAddress correspondence to this author at: Department of Internal Medicine IV, Clinical Chemistry (Central Laboratory), University of Tuebingen, Hoppe-Seyler-Str. 3, D-72076 Tuebingen, Germany. Fax 49-7071-29-4696; e-mail Karsten.Muessig@med.uni-tuebingen.de.

The first 20% of the full text of this article appears below.


To the Editor:

Plasma catecholamines are routinely assayed for the detection of pheochromocytoma and in clinical trials evaluating hemodynamic function in intensive care patients (1). HPLC combined with electrochemical detection is widely applied for the quantification of plasma catecholamines(2). We use a commercially available method for plasma catecholamine measurement (Chromsystems), including a pretreatment step for plasma samples that uses the relative nonspecific absorption of analytes onto Al2O3. Isocratic separation is then performed on a reversed-phase C18 column. Assay conditions include a 0.8 mL/min flow rate and a mobile phase containing salts, methanol, and an ion-pairing reagent. Quantification is performed with an L 3500 electrochemical detector (Recipe) at a potential of +500 mV. 3,4-Dihydroxybenzylamine (DHBA) is used as the internal standard.

We observed an interference with the internal standard in patients taking part in a clinical study in our intensive care unit. Evaluation of the case histories revealed that these patients have received dopamine intravenously . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.